A key cancer-fighting gene in leukemia is switched off—not broken—and scientists from The Jackson Laboratory (JAX) have found a way to switch it back on. In a study published in Science Translational ...
For years, treatment of older patients with acute myeloid leukemia—an aggressive cancer of the blood and bone marrow—has ...
Acute myeloid leukemia (AML) is one of the most aggressive blood cancers and is characterized by the rapid growth of immature myeloid precursor cells. It predominantly affects elderly people, and ...
Scientists from the German Cancer Research Center (DKFZ) and the HI-STEM* Stem Cell Institute have deciphered a key mechanism that contributes to treatment failure in acute myeloid leukemia (AML).
Acute myeloid leukemia (AML) is an aggressive blood cancer characterized by the accumulation of immature myeloid cells. Current treatments often fail to achieve durable remission, underscoring the ...
A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people with acute myeloid leukemia (AML) overcome resistance to one of the most ...
Measurable residual disease (MRD) assessment plays a critical role in monitoring acute myeloid leukemia (AML) progression and relapse risk. Current standard-of-care approaches, including ...
The ASCERTAIN V clinical trial demonstrated that an all-oral drug combination for older patients with acute myeloid leukemia ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results